Nexletol (bempedoic acid) and Nexlizet (bempedoic acid/ezetimibe) are approved for the treatment of:

- Established atherosclerotic cardiovascular disease, as an adjunct to diet and maximally tolerated statin therapy, in adult patients who require additional lowering of low-density lipoprotein cholesterol (LDL-C).
- Established atherosclerotic cardiovascular disease, as an adjunct to diet and maximally tolerated statin therapy, in adult patients who require additional lowering of low-density lipoprotein cholesterol (LDL-C).

Coverage Guidelines
Authorization may be reviewed on a case by case basis for members new to AllWays Health Partners who are currently receiving treatment with the requested medication excluding when the product is obtained as samples or via manufacturer’s patient assistance programs.

**OR**
Authorization may be granted for members when ALL the following criteria are met, and documentation is provided:
1. The member is ≥ 18 years of age
2. The member ONE of the following diagnosis:
   a. Established atherosclerotic cardiovascular disease
   b. Heterozygous familial hypercholesterolemia
3. The member is using requested medication as adjunct to diet
4. The member meets ONE of the following:
a. Inadequate response to a combination of the following high dose statin (atorvastatin 80mg OR rosuvastatin 40mg) with ezetimibe for a consecutive 3 months
b. Clinical documentation of adverse effect/contraindication to high dose statin

**Continuation of Therapy**
Reauthorization requires physician documentation of improvement of member’s condition.

**Limitations**
1. Initial approvals and reauthorizations will be granted for 24 months.
2. The following quantity limits apply:

<table>
<thead>
<tr>
<th>Medication</th>
<th>Quantity Limit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nexletol</td>
<td>30 tablets per 30 days</td>
</tr>
<tr>
<td>Nexlizet 180mg-10mg</td>
<td>30 tablets per 30 days</td>
</tr>
</tbody>
</table>

**References**
1. Nexletol (bempedoic acid) [prescribing information]. Ann Arbor, MI: Esperion Therapeutics Inc; February 2020.
2. Nexlizet (bempedoic acid and ezetimibe) [prescribing information]. Ann Arbor, MI: Esperion Therapeutics Inc; February 2020.

**Review History**
01/20/2021 – Created and reviewed for Jan P&T. Effective 02/01/21.

**Disclaimer**
AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.